Research advances in mechanism of antiangiogenic therapy combined with immune checkpoint inhibitors for treatment of non-small cell lung cancer

Immunotherapy has changed the treatment strategy of non-small cell lung cancer (NSCLC) in recent years, among which anti-PD-1/PD-L1 antibodies are the most used. However, the majority of patients with NSCLC do not derive benefit from immune checkpoint inhibitors (ICIs). Vascular abnormalities are a...

Descripción completa

Detalles Bibliográficos
Autores principales: He, Danming, Wang, Lu, Xu, Jiachen, Zhao, Jie, Bai, Hua, Wang, Jie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10618022/
https://www.ncbi.nlm.nih.gov/pubmed/37915579
http://dx.doi.org/10.3389/fimmu.2023.1265865

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10618022/
https://www.ncbi.nlm.nih.gov/pubmed/37915579
http://dx.doi.org/10.3389/fimmu.2023.1265865

Ejemplares similares